S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.86 (-1.83%)
MSFT   312.00 (-1.74%)
META   298.96 (-0.62%)
GOOGL   127.80 (-2.52%)
AMZN   127.30 (-3.02%)
TSLA   247.08 (+0.04%)
NVDA   421.86 (-0.09%)
NIO   8.51 (+1.92%)
BABA   86.24 (-1.12%)
AMD   96.12 (-1.29%)
T   15.04 (-0.13%)
F   12.52 (-0.48%)
MU   68.19 (-0.57%)
CGC   0.93 (-1.35%)
GE   109.97 (-1.57%)
DIS   80.54 (-0.58%)
AMC   8.17 (+0.37%)
PFE   32.82 (-0.49%)
PYPL   59.05 (+0.32%)
NFLX   382.94 (-0.48%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.86 (-1.83%)
MSFT   312.00 (-1.74%)
META   298.96 (-0.62%)
GOOGL   127.80 (-2.52%)
AMZN   127.30 (-3.02%)
TSLA   247.08 (+0.04%)
NVDA   421.86 (-0.09%)
NIO   8.51 (+1.92%)
BABA   86.24 (-1.12%)
AMD   96.12 (-1.29%)
T   15.04 (-0.13%)
F   12.52 (-0.48%)
MU   68.19 (-0.57%)
CGC   0.93 (-1.35%)
GE   109.97 (-1.57%)
DIS   80.54 (-0.58%)
AMC   8.17 (+0.37%)
PFE   32.82 (-0.49%)
PYPL   59.05 (+0.32%)
NFLX   382.94 (-0.48%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.86 (-1.83%)
MSFT   312.00 (-1.74%)
META   298.96 (-0.62%)
GOOGL   127.80 (-2.52%)
AMZN   127.30 (-3.02%)
TSLA   247.08 (+0.04%)
NVDA   421.86 (-0.09%)
NIO   8.51 (+1.92%)
BABA   86.24 (-1.12%)
AMD   96.12 (-1.29%)
T   15.04 (-0.13%)
F   12.52 (-0.48%)
MU   68.19 (-0.57%)
CGC   0.93 (-1.35%)
GE   109.97 (-1.57%)
DIS   80.54 (-0.58%)
AMC   8.17 (+0.37%)
PFE   32.82 (-0.49%)
PYPL   59.05 (+0.32%)
NFLX   382.94 (-0.48%)
S&P 500   4,290.89 (-1.07%)
DOW   33,715.62 (-0.86%)
QQQ   355.34 (-1.19%)
AAPL   172.86 (-1.83%)
MSFT   312.00 (-1.74%)
META   298.96 (-0.62%)
GOOGL   127.80 (-2.52%)
AMZN   127.30 (-3.02%)
TSLA   247.08 (+0.04%)
NVDA   421.86 (-0.09%)
NIO   8.51 (+1.92%)
BABA   86.24 (-1.12%)
AMD   96.12 (-1.29%)
T   15.04 (-0.13%)
F   12.52 (-0.48%)
MU   68.19 (-0.57%)
CGC   0.93 (-1.35%)
GE   109.97 (-1.57%)
DIS   80.54 (-0.58%)
AMC   8.17 (+0.37%)
PFE   32.82 (-0.49%)
PYPL   59.05 (+0.32%)
NFLX   382.94 (-0.48%)
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News

$60.92
+2.06 (+3.50%)
(As of 12:15 PM ET)
Compare
Today's Range
$60.02
$61.44
50-Day Range
$58.86
$70.72
52-Week Range
$57.77
$97.65
Volume
31,434 shs
Average Volume
105,846 shs
Market Capitalization
$1.06 billion
P/E Ratio
42.31
Dividend Yield
N/A
Price Target
$109.75

Ligand Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.5% Upside
$109.75 Price Target
Short Interest
Bearish
5.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.47mentions of Ligand Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$237,520 Bought Last Quarter
Proj. Earnings Growth
-24.46%
From $3.68 to $2.78 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

130th out of 961 stocks

Pharmaceutical Preparations Industry

41st out of 454 stocks


LGND stock logo

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

LGND Price History

LGND Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Where Ligand Pharmaceuticals Stands With Analysts
Craig-Hallum Reaffirms Their Buy Rating on Ligand Pharma (LGND)
Ligand: Nothing Exciting Stands Out
Analyst Expectations for Ligand Pharmaceuticals's Future
Ligand Pharmaceuticals Inc Q2 Earnings Summary
Ligand Reports Second Quarter 2023 Financial Results
Ligand (LGND) to Post Q2 Earnings: What's in Store?
See More Headlines
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$109.75
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+86.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-33,360,000.00
Pretax Margin
50.96%

Debt

Sales & Book Value

Annual Sales
$196.24 million
Cash Flow
$5.07 per share
Book Value
$35.37 per share

Miscellaneous

Free Float
15,550,000
Market Cap
$1.02 billion
Optionable
Optionable
Beta
1.02
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Todd C. Davis Ph.D. (Age 62)
    CEO & Director
    Comp: $743.49k
  • Mr. Matthew E. Korenberg (Age 48)
    Pres & COO
    Comp: $760.99k
  • Mr. Octavio Espinoza (Age 52)
    Chief Financial Officer
    Comp: $457.19k
  • Mr. Andrew T. Reardon J.D. (Age 48)
    Chief Legal Officer & Sec.
    Comp: $480.16k
  • Simon Latimer
    Head of Investor Relations
  • Mr. Todd Pettingill
    Director of Corp. Devel.
  • Ms. Audrey Warfield-Graham
    Chief People Officer
  • Dr. Keith Marschke
    Sr. VP of Biology & Scientific Affairs
  • Dr. Vincent D. Antle (Age 54)
    Sr. VP of Technical Operations & QA - Capitsol
  • Mr. Patrick Lucy
    Sr. VP & CBO Protein Expression Bus.













LGND Stock - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 12 month price targets for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $144.00. On average, they anticipate the company's share price to reach $109.75 in the next twelve months. This suggests a possible upside of 86.5% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2023?

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND shares have decreased by 11.9% and is now trading at $58.86.
View the best growth stocks for 2023 here
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our LGND earnings forecast
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $0.76 by $0.66. The biotechnology company had revenue of $26.37 million for the quarter, compared to the consensus estimate of $24.74 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 6.82% and a net margin of 14.54%. The business's revenue was down 47.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.14) EPS.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY23 earnings guidance on Monday, September, 18th. The company provided EPS guidance of $5.10-5.25 for the period, compared to the consensus EPS estimate of $4.97. The company issued revenue guidance of $124-126 million, compared to the consensus revenue estimate of $127.17 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.83%), State Street Corp (3.53%), Dimensional Fund Advisors LP (3.08%), Villere ST Denis J & Co. LLC (2.78%), Stephens Investment Management Group LLC (2.69%) and Chicago Capital LLC (2.46%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $58.86.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.02 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.44 on an earnings per share basis.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -